Press Releases

– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 o bservation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at

New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an

BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the

– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd   – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced

- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 - BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research &

Data support continued advancement of LB101 toward IND submission late this year BOSTON and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc  (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover,

BOSTON & LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that

- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced